Advertisement

A critical review of the reproductive safety of Leflunomide

  • Birgit Pfaller
  • Anna Pupco
  • Tom Leibson
  • Daniel Aletaha
  • Shinya ItoEmail author
Perspectives in Rheumatology

Abstract

Leflunomide, an inhibitor of pyrimidine synthesis, is used for the treatment of rheumatic diseases, which are prevalent in women of childbearing age. Due to the very long half-life of the active metabolite, its mechanism of action and the teratogenicity observed in animal studies at doses similar to or lower than human therapeutic doses on a weight basis, it is recommended that women stop the treatment before conception and a drug elimination procedure be performed. However, unintended gestational exposures may occur, posing challenges in risk assessment. In order to address the safety of leflunomide in unintended exposures in pregnancy, we performed a critical review of human studies. We located 13 publications in Medline and Embase, which reported on 222 pregnancies with known outcomes exposed to leflunomide preconception and/or during pregnancy. Among the 169 live births, there were eight congenital malformations with no consistent pattern of anomalies. These studies collectively showed no significant difference in the rates of malformations between exposed and unexposed pregnancies. At present, accumulating human data do not point toward leflunomide as a potent human teratogen, which may inform risk assessment of unintended gestational exposure to leflunomide.

Keywords

Congenital anomalies Leflunomide Pregnancy Rheumatic disease Safety Teratogen 

Notes

Compliance with ethical standards

Disclosures

S. Ito received a grant from UCB Pharma GmbH and a consultant fee from AbbVie.

D. Aletaha received speaker and/or consultancy fees from Abbvie, Amgen, Celgene, Lilly, Medac, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi/Genzyme and grants from AbbVie, Novartis, Roche.

References

  1. 1.
    Gotestam Skorpen C et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810CrossRefGoogle Scholar
  2. 2.
    Arava (leflunomide) prescribing information. Bridgewater (NJ): Sanofi-Aventis. URL: http://products.sanofi.us/arava/arava.html
  3. 3.
    Holmes LB (2011) Human teratogens: update 2010. Birth Defects Res A Clin Mol Teratol. 91(1):1–7CrossRefGoogle Scholar
  4. 4.
    Brent RL (2001) Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 63(2):106–112CrossRefGoogle Scholar
  5. 5.
    Fukushima R et al (2007) Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor leflunomide in mice. Reprod Toxicol 24(3-4):310–316CrossRefGoogle Scholar
  6. 6.
    Fox RI, Herrmann ML, Frangou CG et al (1999) Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93:198–208CrossRefGoogle Scholar
  7. 7.
    Fukushima R et al (2009) Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine. Toxicol Sci 108(2):419–426CrossRefGoogle Scholar
  8. 8.
    Aventis Pharmaceuticals Inc. Arava Tablets (leflunomide). Contraindications and warnings. Available from: http://www.accessdata.fda.gov/drugsatfdadocs/label/2003/20905slr007,20905se1-006 arava lbl.pdf 2003 [cited31.10.16]
  9. 9.
    Ng SB et al (2010) Exome sequencing identifies the cause of a mendelian disorder. Nat Genet 42(1):30–35CrossRefGoogle Scholar
  10. 10.
    Berard A et al (2018) Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis 77(4):500–509CrossRefGoogle Scholar
  11. 11.
    Chambers CD et al (2010) Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 62(5):1494–1503CrossRefGoogle Scholar
  12. 12.
    Cassina M et al (2012) Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 64(7):2085–2094CrossRefGoogle Scholar
  13. 13.
    Weber-Schoendorfer C et al (2017) Leflunomide - a human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database. Reprod Toxicol 71:101–107CrossRefGoogle Scholar
  14. 14.
    Viktil KK, Engeland A, Furu K (2012) Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol. 41(3):196–201CrossRefGoogle Scholar
  15. 15.
    De Santis M et al (2005) Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheum Dis 64(7):1096–1097CrossRefGoogle Scholar
  16. 16.
    Chakravarty EF, Sanchez-Yamamoto D, Bush TM (2003) The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol. 30:241–246PubMedGoogle Scholar
  17. 17.
    Paulus W, Schloemp S, Sterzik K (2006) The use of leflunomide in fertile patients with rheumatoid arthritis [abstract]. Reprod. Toxicol. 22:281Google Scholar
  18. 18.
    Karadag O, Kilic L, Erbil AA et al (2013) Pregnancy outcomes of rheumatic patients with pre/peri gestational leflunomide exposure. Ann Rheum Dis 72(Suppl 3):A896–A897Google Scholar
  19. 19.
    Kraemer B, Abele H, Hahn M, Rajab T, Kraemer E, Wallweiner D et al (2008) A successful pregnancy in a patient with Takayasu’s arteritis. Hypertens Pregnancy. 27(3):247–252CrossRefGoogle Scholar
  20. 20.
    Hajdyla-Banas I, Banas T, Rydz-Stryszowska I, Batko B, Skura A, Gornisiewicz T et al (2009) Pregnancy course and neonatal outcome after exposure to leflunomide--2 cases report and review of literature. Przegl Lek. 66(12):1069–1071PubMedGoogle Scholar
  21. 21.
    Sayarlioglu M et al (2010) Maternal exposure to leflunomide and methotrexate in a patient with adult-onset Still’s disease. Rheumatology (Oxford) 49(9):1787–1789CrossRefGoogle Scholar
  22. 22.
    Heine K, Poets CF (2008) A pair of twins born after maternal exposure to leflunomide. J Perinatol 28(12):841–842CrossRefGoogle Scholar
  23. 23.
    Neville CE, McNally J (2007) Maternal exposure to leflunomide associated with blindness and cerebral palsy. Rheumatology (Oxford) 46(9):1506CrossRefGoogle Scholar
  24. 24.
    Keeling, S.O. and A.E. Oswald, Pregnancy and rheumatic disease: “by the book” or “by the doc”. Clin Rheumatol, 2009. 28(1): p. 1-9.CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Toronto Pregnancy and Heart Disease Research Program, Mount Sinai Hospital and Toronto General HospitalTorontoCanada
  2. 2.Division of Clinical Pharmacology and Toxicology, Department of PediatricsHospital for Sick ChildrenTorontoCanada
  3. 3.Department of PediatricsMount Sinai HospitalTorontoCanada
  4. 4.Department of RheumatologyMedical University of ViennaViennaAustria

Personalised recommendations